Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 1998

View Archived Issues

Pfizer reports pharmacokinetics of a novel anxiolytic agent - CP-93393

Novel antimicrobial lipid compounds for preventing STDs

Phase I trial reports efficacy of chimeric MAb CH-14.18 in neuroblastoma

Risperidone: satellite symposia discuss impact on cognition and behavior

Phase II clinical trial begins for fibromyalgia treatment

AltaRex initiates second phase II trial of OvaRex

Vical and NCI initiate melanoma DNA vaccine trial

CNS compounds from ADIR that selectively bind to D4 receptors

ADIR discloses cytotoxic anthracene derivatives for leukemia and solid tumors

Cephalosporins described by Roche for Gram-positive infections

Lilly team claims metabotropic glutamate receptor antagonists

Protein tyrosine kinase inhibitors claimed by Pfizer for hyperproliferative disorders

PNU-37883A, a tool for studying the role of K-ATP in renin release

Schering-Plough, Immune Response collaborate to develop hepatitis gene therapy

ICN develops compound for treatment of NSAID-induced ulcers

LG-120907, a potent antiandrogen with reduced adverse effects

Vasomax NDA submitted for FDA review

More telomerase inhibitors added to the Geron pipeline

Nexell's Isolex technology receives U.S. patent protection; FDA requests more data

SU-101 enters phase II testing in ovarian cancer patients

Synthesis of new COX-2 inhibitor described by Merck scientists

NIH supports Atrix in development of new-generation dental product

Amylin completes enrollment in U.S. for phase III pramlintide studies

Clopidogrel approved throughout European Union

Venlafaxine relieves anxiety; more cost-effective than other antidepressants

Genetronics develops TDD method for treating ED, seeks partners to carry on

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...